On this page ▾
The market expects Torrent Pharma to do better than it ever has.
At today’s share price, buyers are assuming Torrent Pharma grows about 18% a year, forever. Over the last ten years it actually grew about 12% a year. So the share price only makes sense if the business improves on its own track record. If it simply carries on as before, buyers today have paid for something they will not get.
- How it is valued: Discounted cash flow.
- What the price assumes: 18% growth, against 12% the model takes from its own record.
- Ten-year record: Between FY2018 and FY2026, Torrent Pharma's revenue went from ₹6,002 crore to ₹13,980 crore — it compounded at about 11% a year over 8 years.
- Biggest swing factor: India branded growth. Main risk: Debt from deals.
01Branded medicines for long-term conditions
Torrent Pharmaceuticals, part of Ahmedabad's Torrent group, earns most of its profit from branded prescription medicines in India, especially for chronic conditions such as heart disease, diabetes and gastric disorders. It also sells in Brazil, Germany and the US.
It has grown repeatedly through acquisitions — including Unichem's India brands and Curatio's dermatology portfolio — and in 2025 agreed to buy a controlling stake in JB Chemicals & Pharmaceuticals.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Torrent Pharma, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Torrent Pharma's record, in plain numbers
Between FY2018 and FY2026, Torrent Pharma's revenue went from ₹6,002 crore to ₹13,980 crore — it compounded at about 11% a year over 8 years. Net profit grew from ₹678 crore to ₹2,138 crore, about 15% a year — faster than revenue, so margins widened. In FY2026 it kept 15.3% of revenue as net profit — against a low of 5.7% in FY2019 and a high of 16.6% in FY2025. The latest year added 21.4% to revenue, well ahead of its own long-run pace.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2018 | 6,002 | 678 | 11.3% |
| FY2019 | 7,673 | 436 | 5.7% |
| FY2020 | 7,939 | 1,025 | 12.9% |
| FY2021 | 8,005 | 1,252 | 15.6% |
| FY2022 | 8,508 | 777 | 9.1% |
| FY2023 | 9,620 | 1,245 | 12.9% |
| FY2024 | 10,728 | 1,656 | 15.4% |
| FY2025 | 11,516 | 1,911 | 16.6% |
| FY2026 | 13,980 | 2,138 | 15.3% |
04How Torrent Pharma gets valued — and why
Discounted cash flowThis business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.
05What decides Torrent Pharma's value
India branded growth
Chronic therapies grow steadily and earn high margins.
Acquisitions
Deals add brands, but only create value if the price is earned back.
Field force productivity
More sales per medical representative lifts margins.
International markets
Brazil and Germany add diversification.
06What could go wrong
- Debt from deals. Large acquisitions add borrowing.
- Price controls. India's drug-price rules cap some products.
- Integration. Bought brands can lose momentum.
07What the full Torrent Pharma valuation shows
Sign in free to see the complete Torrent Pharma valuation
- ✓Fair value per share — from a ten-year discounted cash flow, every step shown
- ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Torrent Pharma's value move
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Sun Pharma, Cipla and Lupin
- ✓Downloadable report — the full write-up, yours to keep
08Compare Torrent Pharma with peers
The same valuation, run side by side.
Torrent Pharma vs Sun PharmaBranded domestic formulations against a US-generics giant.→Torrent Pharma vs CiplaThe closest peer on India-weighted branded sales.→Torrent Pharma vs LupinBranded India against a heavier US-generics book.→09Questions people ask about Torrent Pharma
What does Torrent Pharma specialise in?
Branded medicines for chronic conditions in India — heart, diabetes, gastric and nervous-system therapies.
Why does Torrent buy other companies?
To add established brands and doctors' prescriptions faster than building them.
Torrent or Sun Pharma — which is better value?
Both are valued on the same cash-flow model; the comparison page sets them side by side.
Is Torrent Pharma overvalued?
At ₹4,670 the market is pricing in roughly 18% sustained growth, against the ~12% its own record supports. That is more than it has delivered, so the price is justified only if the business can hold a rate it has not previously sustained.
What is the intrinsic value of Torrent Pharma?
It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.
How much debt does Torrent Pharma carry?
Debt to equity stands at 1.42, against 0.41 at the start of the period — the balance sheet is a core input to the cost of capital used here.